Common Contracts

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • April 7th, 2023

• Contract Type
  Co-Promotion Agreement
• Filed
  April 7th, 2023

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin

Co-Promotion Agreement • May 3rd, 2021

• Contract Type
  Co-Promotion Agreement
• Filed
  May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.